Soligenix Inc. (NASDAQ: SNGX), a biopharmaceutical company specializing in rare diseases, has announced successful results from its Phase 2a proof of concept study for SGX945 (dusquetide) in treating Behçet’s Disease. The study met its primary objective by demonstrating biological efficacy, with SGX945 showing a 40% improvement in the primary ulcer endpoint compared to a historical placebo group from the apremilast (Otezla(R)) Phase 3 study. Notably, these outcomes were achieved despite the treatment duration being limited to four weeks.
Seven out of eight patients in the open-label trial reported reductions in ulcer duration, number, and pain, with the benefits persisting throughout the follow-up period. Importantly, no treatment-related adverse events were reported, underscoring the potential safety profile of SGX945. Christopher J. Schaber, CEO of Soligenix, highlighted that these results support the advancement of SGX945, including its reformulation for home-based subcutaneous administration, as part of a broader strategy to tackle unmet needs in Behçet’s Disease and other innate immune-related inflammatory conditions.
The success of SGX945 in this Phase 2a study is a significant milestone for Soligenix and for patients suffering from Behçet’s Disease, a rare and chronic condition that causes inflammation in blood vessels throughout the body. The positive outcomes suggest that SGX945 could offer a new therapeutic option for this patient population, potentially improving quality of life and reducing the burden of the disease.
For more information on Soligenix and its pipeline, visit https://www.Soligenix.com. Additional details on the study and Soligenix’s other developments can be found in the company’s newsroom at https://ibn.fm/SNGX.
